Early clinical research
Elironrasib + daraxonrasib — RAS(ON) combination (phase I/II)
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients With Advanced Solid Tumors
- Phase
- Phase I/II
- Recruitment
- Recruiting
- Results maturity
- No results
- Publication
- No publication
- Regulatory approval
- No regulatory approval
- NCT
- NCT06128551
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? Researchers are testing whether next-generation RAS drugs can be combined safely.
Why promising? Tests combined/sequential RAS(ON) inhibitors in early clinical development.
What is not proven? No efficacy claim; look to RASolute 302 for phase III readout.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
Early phase (I/II); recruiting. No efficacy claim — RASolute 302 is separate.
Cancer / population: Pancreas, Multiple / solid tumors — İleri solid tümörler (RAS mutant; protokol)
Intervention: Elironrasib ve/veya daraxonrasib
Primary endpoint: Güvenlik / RP2D
Limitations: Erken faz; pankreas dışı solid tümörler karışabilir.